ÂÜŔňÂŇÂ×

Edward T. Kisak has served as CSO of Tioga Research since its founding. He has over ten years of experience in topical formulation development, having served in both managerial and lead scientist roles.  Ed has a PhD in Chemical Engineering from the University of California, Santa Barbara where his doctoral research focused on developing “vesosomes” – a multiplexed liposomal structure containing liposomes nested within other liposomes for advanced drug delivery therapies. This doctoral research was later pursued by Advanced Encapsulation – a start-up company co-founded by Ed to improve and develop the vesosome technology. Ed also served as consultant to Sinus Pharmaceuticals and reformulated their lead tobramycin sinusitis formulation, which later went on to clinical trials. After joining fqubed (later acquired by Nuvo Research, CA:NRI) in 2005, Ed acted as Director of Research, and was responsible for laboratory operations and for managing formulation innovation and skin delivery screening campaigns. During this tenure, Ed acted as the lead formulation scientist on developing PENNSAID® 2% (currently approved in the US for the treatment of osteoarthritis) along with other formulations in Nuvo’s pipeline. Additionally, he was the prime driving force behind the development, optimization and production-mode use of Tioga Research’s HTE platforms, including INSIGHT, STORM, SPATE, SPLASH, TORNADO, MONSOON and SKIVER. He is an inventor on more than 15 issued and pending patents, including that claiming the PENNSAID® 2% formulation.